Comparison · NCT00095576-sae
Trivalent MRKAd5 HIV-1 Gag/Pol/Nef vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Trivalent MRKAd5 HIV-1 Gag/Pol/Nef vs Placebo: serious adverse events. Trial comparisons, record NCT00095576-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00095576-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0128 | 0.00821 | 0.0199 | wilson | |
| Risk in group 2 | 0.0114 | 0.00711 | 0.0181 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00143 | -0.00674 | 0.00972 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.13 | 0.588 | 2.16 | log | |
| Odds ratio, group 1 over group 2 | 1.13 | 0.584 | 2.18 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Trivalent MRKAd5 HIV-1 Gag/Pol/Nef than on Placebo | 698 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Trivalent MRKAd5 HIV-1 Gag/Pol/Nef | Participants randomized to receive three 1.0-ml intramuscular (IM) injections of Merck Trivalent Adenovirus Serotype 5 HIV-1 gag/pol/nef (MRKAd5 HIV-1 gag/pol/nef) Vaccine at a dose of 1.5x10\^10 adenovirus genomes (Ad vg) per dose at Day 1, Week 4, and Week 26. | 19 | 1,484 | EG000 |
| Group 2 | Placebo | Participants randomized to receive three 1.0-ml intramuscular (IM) injections of placebo to MRKAd5 HIV-1 gag/pol/nef at Day 1, Week 4, and Week 26. | 17 | 1,495 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Source ClinicalTrials.gov
Trial
- Title
- Investigation of V520 in an HIV Vaccine Proof-of-Concept Study (V520-023)
- NCT number
- NCT00095576
- Phases
- PHASE2
- Conditions
- AIDS, HIV Infections
- Interventions
- Trivalent MRKAd5 HIV-1 gag/pol/nef (1.5x10^10 ad-vg/dose), Comparator: placebo
- Lead sponsor
- Merck Sharp & Dohme LLC
- Results first posted
- 2011-08-15
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00095576?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00095576-sae